Date of publication: 29 July 2022 Approval of the Secretary of health: 31 August 2022 Link to the Evidence summary HTAC Recommendation preview:
Insulin glargine (100 IU/mL, 10 mL vial and 3 mL pre-filled pen) for Type 1 and Type 2 Diabetes Mellitus
Preliminary Recommendation for the Inclusion of Insulin Glargine and Insulin Detemir for Type 1 and Type 2 Diabetes Mellitus in the PNF Link to the Evidence Summary: Evidence Summary on insulin glargine and detemir for type 1 and type 2 diabetes mellitus Link to appeals form here: https://hta.doh.gov.ph/topic-nomination/ (stakeholders may submit appeals to hta@doh.gov.ph until 11 August 2022.) Document Preview:
Insulin detemir (100 U/mL) for Type 1 and Type 2 Diabetes Mellitus
Preliminary Recommendation for the Inclusion of Insulin Glargine and Insulin Detemir for Type 1 and Type 2 Diabetes Mellitus in the PNF Link to the Evidence Summary: Evidence Summary on insulin glargine and detemir for type 1 and type 2 diabetes mellitus Link to appeals form here: https://hta.doh.gov.ph/topic-nomination/ (stakeholders may submit appeals to hta@doh.gov.ph until 11 August 2022.)
HTAC Guidance on COVID-19 Boosters for the Adolescent Population
As of 11 July 2022 What is the HTAC recommendation? On June 14, the Philippine Food and Drug Administration (FDA) granted the Pfizer-BioNTech COVID-19 vaccine an Emergency Use Authorization (EUA) for the adolescent population ages 12 to 17 years. Thereafter, the Health Technology Assessment Council (HTAC) evaluated this vaccine for inclusion in the COVID-19 National Vaccination Deployment continue reading : HTAC Guidance on COVID-19 Boosters for the Adolescent Population